MARAGANORE JOHN

Director at ALNYLAM PHARMACEUTICALS, INC. · on record since May 16, 2006
Director at TAKEDA PHARMACEUTICAL CO LTD · on record since Mar 18, 2026
President and CEO at ALNYLAM PHARMACEUTICALS, INC. · on record since May 27, 2004
Director at Hemab Therapeutics Holdings, Inc. · on record since Apr 30, 2026
Director at Regulus Therapeutics Inc. · on record since Oct 11, 2012
10% owner at Regulus Therapeutics Inc. · on record since Oct 11, 2012
Director at BLUE HOLDINGS, INC. · on record since Jun 18, 2013
Director at ALKERMES INC · on record since Sep 24, 2013
Chief Executive Officer at ALKERMES INC · on record since Sep 24, 2013
Director at AGIOS PHARMACEUTICALS, INC. · on record since Jul 23, 2013
Director at Beam Therapeutics Inc. · on record since Jun 5, 2026
Director at Rapport Therapeutics, Inc. · on record since Jun 10, 2026
Director at Kymera Therapeutics, Inc. · on record since Jan 19, 2022
Director at PROKIDNEY CORP. · on record since Jul 13, 2022

Insider trading activity of MARAGANORE JOHN

Transactions on record: 604; since Aug 26, 2004

Open-market buys: 17; $1.9M

Open-market sells: 322; $135.8M

Companies traded: 10; last filing Jun 25, 2026

Figures computed from official regulatory filings — methodology.

Companies where MARAGANORE JOHN has traded

TAKEDA PHARMACEUTICAL CO LTD2 tx · Jul 6, 2026
Kymera Therapeutics, Inc.5 tx · Jun 25, 2026
Rapport Therapeutics, Inc.2 tx · Jun 10, 2026
Beam Therapeutics Inc.6 tx · Jun 5, 2026
Hemab Therapeutics Holdings, Inc.5 tx · May 4, 2026
PROKIDNEY CORP.3 tx · Jul 3, 2023
AGIOS PHARMACEUTICALS, INC.35 tx · $550.2K · Feb 3, 2023
ALNYLAM PHARMACEUTICALS, INC.522 tx · $161.5M · Dec 23, 2021
BLUE HOLDINGS, INC.23 tx · $5.4M · Sep 18, 2017

Track record of MARAGANORE JOHN

Statistical track record

Free

Open-market buys: 17

Last buy: Jan 26, 2015

Win rates and median returns are available with a free account (5 insiders/month).

Create a free account

Transaction history of MARAGANORE JOHN

Co-insiders of MARAGANORE JOHN

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

Company	Filed	Type	Qty	Price	Value · USD	Src
TAKEDA PHARMACEUTICAL CO LTD	Jul 6, 2026	AwardD	1,319	0.00 USD	—	SEC
TAKEDA PHARMACEUTICAL CO LTD	Jul 6, 2026	Award	3,800	0.00 USD	—	SEC
Kymera Therapeutics, Inc.	Jun 25, 2026	AwardD	6,068	0.00 USD	—	SEC
Rapport Therapeutics, Inc.	Jun 10, 2026	AwardD	15,200	0.00 USD	$0	SEC
Beam Therapeutics Inc.	Jun 5, 2026	AwardD	19,676	0.00 USD	$0	SEC
Hemab Therapeutics Holdings, Inc.	May 4, 2026	AwardD	107,338	0.00 USD	$0	SEC
Hemab Therapeutics Holdings, Inc.	May 4, 2026	OtherD	-817	0.00 USD	$0	SEC
Hemab Therapeutics Holdings, Inc.	May 4, 2026	Other	17,974	—	—	SEC
Hemab Therapeutics Holdings, Inc.	May 4, 2026	Other	17,974	—	—	SEC
Hemab Therapeutics Holdings, Inc.	May 4, 2026	OtherD	-817	0.00 USD	$0	SEC
Kymera Therapeutics, Inc.	Jun 26, 2025	AwardD	16,000	0.00 USD	$0	SEC
Rapport Therapeutics, Inc.	Jun 18, 2025	AwardD	21,850	0.00 USD	$0	SEC
Beam Therapeutics Inc.	Jun 6, 2025	AwardD	33,662	0.00 USD	$0	SEC
Kymera Therapeutics, Inc.	Jun 20, 2024	AwardD	16,000	0.00 USD	$0	SEC
Beam Therapeutics Inc.	Jun 7, 2024	AwardD	23,114	0.00 USD	$0	SEC
PROKIDNEY CORP.	Jul 3, 2023	AwardD	48,128	0.00 USD	$0	SEC
Kymera Therapeutics, Inc.	Jun 20, 2023	AwardD	12,000	0.00 USD	$0	SEC
Beam Therapeutics Inc.	Jun 8, 2023	AwardD	16,532	0.00 USD	$0	SEC
AGIOS PHARMACEUTICALS, INC.	Feb 3, 2023	Gift	-1,500	0.00 USD	$0	SEC
Beam Therapeutics Inc.	Sep 2, 2022	AwardD	10,391	0.00 USD	$0	SEC
PROKIDNEY CORP.	Jul 13, 2022	AwardD	614,013	0.00 USD	$0	SEC
PROKIDNEY CORP.	Jul 13, 2022	AwardD	614,013	0.00 USD	$0	SEC
AGIOS PHARMACEUTICALS, INC.	Jun 23, 2022	AwardD	4,975	0.00 USD	$0	SEC
AGIOS PHARMACEUTICALS, INC.	Jun 23, 2022	AwardD	29,307	0.00 USD	$0	SEC
AGIOS PHARMACEUTICALS, INC.	May 24, 2022	ExerciseD	-1,585	0.00 USD	$0	SEC

Company	Filed	Type	Qty	Price	Value · USD	Src
TAKEDA PHARMACEUTICAL CO LTD	Jul 6, 2026	AwardD	1,319	0.00 USD	—	SEC
TAKEDA PHARMACEUTICAL CO LTD	Jul 6, 2026	Award	3,800	0.00 USD	—	SEC
Kymera Therapeutics, Inc.	Jun 25, 2026	AwardD	6,068	0.00 USD	—	SEC
Rapport Therapeutics, Inc.	Jun 10, 2026	AwardD	15,200	0.00 USD	$0	SEC
Beam Therapeutics Inc.	Jun 5, 2026	AwardD	19,676	0.00 USD	$0	SEC
Hemab Therapeutics Holdings, Inc.	May 4, 2026	AwardD	107,338	0.00 USD	$0	SEC
Hemab Therapeutics Holdings, Inc.	May 4, 2026	OtherD	-817	0.00 USD	$0	SEC
Hemab Therapeutics Holdings, Inc.	May 4, 2026	Other	17,974	—	—	SEC
Hemab Therapeutics Holdings, Inc.	May 4, 2026	Other	17,974	—	—	SEC
Hemab Therapeutics Holdings, Inc.	May 4, 2026	OtherD	-817	0.00 USD	$0	SEC
Kymera Therapeutics, Inc.	Jun 26, 2025	AwardD	16,000	0.00 USD	$0	SEC
Rapport Therapeutics, Inc.	Jun 18, 2025	AwardD	21,850	0.00 USD	$0	SEC
Beam Therapeutics Inc.	Jun 6, 2025	AwardD	33,662	0.00 USD	$0	SEC
Kymera Therapeutics, Inc.	Jun 20, 2024	AwardD	16,000	0.00 USD	$0	SEC
Beam Therapeutics Inc.	Jun 7, 2024	AwardD	23,114	0.00 USD	$0	SEC
PROKIDNEY CORP.	Jul 3, 2023	AwardD	48,128	0.00 USD	$0	SEC
Kymera Therapeutics, Inc.	Jun 20, 2023	AwardD	12,000	0.00 USD	$0	SEC
Beam Therapeutics Inc.	Jun 8, 2023	AwardD	16,532	0.00 USD	$0	SEC
AGIOS PHARMACEUTICALS, INC.	Feb 3, 2023	Gift	-1,500	0.00 USD	$0	SEC
Beam Therapeutics Inc.	Sep 2, 2022	AwardD	10,391	0.00 USD	$0	SEC
PROKIDNEY CORP.	Jul 13, 2022	AwardD	614,013	0.00 USD	$0	SEC
PROKIDNEY CORP.	Jul 13, 2022	AwardD	614,013	0.00 USD	$0	SEC
AGIOS PHARMACEUTICALS, INC.	Jun 23, 2022	AwardD	4,975	0.00 USD	$0	SEC
AGIOS PHARMACEUTICALS, INC.	Jun 23, 2022	AwardD	29,307	0.00 USD	$0	SEC
AGIOS PHARMACEUTICALS, INC.	May 24, 2022	ExerciseD	-1,585	0.00 USD	$0	SEC